In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500 and Nasdaq Composite indices tumbled over 1.5% due to lingering inflation concerns and a surprise hawkish pivot
Could Regeneron Pharmaceuticals be the next big winner in biotech? Join us as we break down the company's strengths, challenges, and future potential in this insightful episode.
INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing stellar long-term clinical data for its atopic dermatitis (eczema) treatment, Ebglyss. The disconnect between the laboratory and the trading
AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster candidate, Tozorakimab. The positive data from the OBERON and TITANIA trials, which evaluated the drug in patients with moderate-to-severe chronic
On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study. The trial, which evaluated the company's lead product candidate Zenkuda™ (tarcocimab tedromer) in patients with diabetic retinopathy (DR), not
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI) for its lead asset, AVLAYAH™ (tividenofusp alfa-eknm). This represents more than just a new treatment for Hunter Syndrome; it marks the first time in medical history that [...]
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining dema...
In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly "sweetened" revised bid for Ocular Therapeutix (NASDAQ: OCUL). The updated offer comes at a high-stakes moment for the biotech industry, as Ocular Therapeutix
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in its final "quiet period" before releasing the highly anticipated topline results for its SOL-1 Phase 3 trial. The data, expected to
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 9.3% gain over the past six months, beating the S&P 500 by 2 percentage points.
The latest Personal Consumption Expenditures (PCE) price index data has revealed a significant shift in the U.S. inflationary landscape, presenting a complex puzzle for the Federal Reserve. As of early February 2026, the data shows a stark divergence: while the services sector—the primary engine of post-pandemic inflation—is
